A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.
Adult
Alcohol Drinking
/ adverse effects
Case-Control Studies
Cohort Studies
Diabetes Mellitus
/ epidemiology
Female
Genetic Predisposition to Disease
/ classification
Genome-Wide Association Study
/ methods
Humans
Liver Cirrhosis, Alcoholic
/ diagnosis
Male
Middle Aged
Polymorphism, Single Nucleotide
/ genetics
Risk Assessment
/ methods
Hepatocellular carcinoma
chronic alcohol use
coffee
genome-wide association
risk stratification
single nucleotide polymorphism
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
25
05
2021
revised:
06
09
2021
accepted:
05
10
2021
pubmed:
18
10
2021
medline:
23
2
2022
entrez:
17
10
2021
Statut:
ppublish
Résumé
Only a minority of excess alcohol drinkers develop cirrhosis. We developed and evaluated risk stratification scores to identify those at highest risk. Three cohorts (GenomALC-1: n = 1,690, GenomALC-2: n = 3,037, UK Biobank: relevant n = 6,898) with a history of heavy alcohol consumption (≥80 g/day (men), ≥50 g/day (women), for ≥10 years) were included. Cases were participants with alcohol-related cirrhosis. Controls had a history of similar alcohol consumption but no evidence of liver disease. Risk scores were computed from up to 8 genetic loci identified previously as associated with alcohol-related cirrhosis and 3 clinical risk factors. Score performance for the stratification of alcohol-related cirrhosis risk was assessed and compared across the alcohol-related liver disease spectrum, including hepatocellular carcinoma (HCC). A combination of 3 single nucleotide polymorphisms (SNPs) (PNPLA3:rs738409, SUGP1-TM6SF2:rs10401969, HSD17B13:rs6834314) and diabetes status best discriminated cirrhosis risk. The odds ratios (ORs) and (95% CIs) between the lowest (Q1) and highest (Q5) score quintiles of the 3-SNP score, based on independent allelic effect size estimates, were 5.99 (4.18-8.60) (GenomALC-1), 2.81 (2.03-3.89) (GenomALC-2), and 3.10 (2.32-4.14) (UK Biobank). Patients with diabetes and high risk scores had ORs of 14.7 (7.69-28.1) (GenomALC-1) and 17.1 (11.3-25.7) (UK Biobank) compared to those without diabetes and with low risk scores. Patients with cirrhosis and HCC had significantly higher mean risk scores than patients with cirrhosis alone (0.76 ± 0.06 vs. 0.61 ± 0.02, p = 0.007). Score performance was not significantly enhanced by information on additional genetic risk variants, body mass index or coffee consumption. A risk score based on 3 genetic risk variants and diabetes status enables the stratification of heavy drinkers based on their risk of cirrhosis, allowing for the provision of earlier preventative interventions. Excessive chronic drinking leads to cirrhosis in some people, but so far there is no way to identify those at high risk of developing this debilitating disease. We developed a genetic risk score that can identify patients at high risk. The risk of cirrhosis is increased >10-fold with just two risk factors - diabetes and a high genetic risk score. Risk assessment using this test could enable the early and personalised management of this disease in high-risk patients.
Sections du résumé
BACKGROUND & AIMS
Only a minority of excess alcohol drinkers develop cirrhosis. We developed and evaluated risk stratification scores to identify those at highest risk.
METHODS
Three cohorts (GenomALC-1: n = 1,690, GenomALC-2: n = 3,037, UK Biobank: relevant n = 6,898) with a history of heavy alcohol consumption (≥80 g/day (men), ≥50 g/day (women), for ≥10 years) were included. Cases were participants with alcohol-related cirrhosis. Controls had a history of similar alcohol consumption but no evidence of liver disease. Risk scores were computed from up to 8 genetic loci identified previously as associated with alcohol-related cirrhosis and 3 clinical risk factors. Score performance for the stratification of alcohol-related cirrhosis risk was assessed and compared across the alcohol-related liver disease spectrum, including hepatocellular carcinoma (HCC).
RESULTS
A combination of 3 single nucleotide polymorphisms (SNPs) (PNPLA3:rs738409, SUGP1-TM6SF2:rs10401969, HSD17B13:rs6834314) and diabetes status best discriminated cirrhosis risk. The odds ratios (ORs) and (95% CIs) between the lowest (Q1) and highest (Q5) score quintiles of the 3-SNP score, based on independent allelic effect size estimates, were 5.99 (4.18-8.60) (GenomALC-1), 2.81 (2.03-3.89) (GenomALC-2), and 3.10 (2.32-4.14) (UK Biobank). Patients with diabetes and high risk scores had ORs of 14.7 (7.69-28.1) (GenomALC-1) and 17.1 (11.3-25.7) (UK Biobank) compared to those without diabetes and with low risk scores. Patients with cirrhosis and HCC had significantly higher mean risk scores than patients with cirrhosis alone (0.76 ± 0.06 vs. 0.61 ± 0.02, p = 0.007). Score performance was not significantly enhanced by information on additional genetic risk variants, body mass index or coffee consumption.
CONCLUSIONS
A risk score based on 3 genetic risk variants and diabetes status enables the stratification of heavy drinkers based on their risk of cirrhosis, allowing for the provision of earlier preventative interventions.
LAY SUMMARY
Excessive chronic drinking leads to cirrhosis in some people, but so far there is no way to identify those at high risk of developing this debilitating disease. We developed a genetic risk score that can identify patients at high risk. The risk of cirrhosis is increased >10-fold with just two risk factors - diabetes and a high genetic risk score. Risk assessment using this test could enable the early and personalised management of this disease in high-risk patients.
Identifiants
pubmed: 34656649
pii: S0168-8278(21)02111-5
doi: 10.1016/j.jhep.2021.10.005
pmc: PMC8803006
mid: NIHMS1748321
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
275-282Subventions
Organisme : NIAAA NIH HHS
ID : U01 AA026917
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA021886
Pays : United States
Organisme : Medical Research Council
ID : MR/R014019/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L006758/1
Pays : United Kingdom
Organisme : NIAAA NIH HHS
ID : U01 AA018389
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA025208
Pays : United States
Organisme : NIAAA NIH HHS
ID : R28 AA012725
Pays : United States
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR 200153
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : CSRD VA
ID : I01 CX000361
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA018389
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 European Association for the Study of the Liver. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest NPC has a number of consulting agreements with and research grants from the pharmaceutical industry but they are not significantly or directly related to this paper. MP receives research funding from various organisations including the MRC and NIHR. He has also received partnership funding for the following: MRC Clinical Pharmacology Training Scheme (co-funded by MRC and Roche, UCB, Eli Lilly and Novartis); a PhD studentship jointly funded by EPSRC and Astra Zeneca; and grant funding from Vistagen Therapeutics. He has also unrestricted educational grant support for the UK Pharmacogenetics and Stratified Medicine Network from Bristol-Myers Squibb and UCB. He has developed an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this. He is part of the IMI Consortium ARDAT (www.ardat.org). None of these funding sources were deployed in the undertaking of this study. TRM has conducted clinical research with AbbVie, Genfit, Gilead, and Merck but none of these are related to this manuscript. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
JHEP Rep. 2021 Mar 30;3(3):100284
pubmed: 34027340
Prog Liver Dis. 1976;5:494-515
pubmed: 775553
Nat Genet. 2010 Jan;42(1):21-3
pubmed: 19946271
Nat Med. 2020 Apr;26(4):549-557
pubmed: 32273609
Am J Gastroenterol. 2019 Oct;114(10):1574-1586
pubmed: 31464740
PLoS Genet. 2020 Apr 13;16(4):e1008629
pubmed: 32282858
Nat Genet. 2015 Dec;47(12):1443-8
pubmed: 26482880
BMJ. 2010 Mar 11;340:c1240
pubmed: 20223873
JAMA. 2019 May 7;321(17):1723-1725
pubmed: 31063562
J Hepatol. 2015 May;62(5):1061-7
pubmed: 25634330
Clin Gastroenterol Hepatol. 2021 Jun 4;:
pubmed: 34091049
N Engl J Med. 2018 Mar 22;378(12):1096-1106
pubmed: 29562163
Nat Genet. 2016 Oct;48(10):1284-1287
pubmed: 27571263
Int J Epidemiol. 1978 Jun;7(2):113-20
pubmed: 681057
Hepatology. 2019 Jul;70(1):231-240
pubmed: 30908678
Hepatology. 2017 Mar;65(3):929-937
pubmed: 27862159
Hepatology. 2020 Jul;72(1):88-102
pubmed: 31630428
Addiction. 1999 Oct;94(10):1551-73
pubmed: 10790907
Am J Gastroenterol. 2019 Feb;114(2):221-232
pubmed: 30353053
Liver Int. 2014 Apr;34(4):495-504
pubmed: 24102757
Hepatology. 2020 Sep;72(3):845-856
pubmed: 32190914
Clin Gastroenterol Hepatol. 2016 Dec;14(12):1831-1838.e3
pubmed: 27320325
Hepatology. 2021 May;73(5):1920-1931
pubmed: 32853455
Hepatology. 2014 Jun;59(6):2170-7
pubmed: 24114809
Am J Gastroenterol. 2015 Jun;110(6):846-56
pubmed: 25964223
J Hepatol. 2021 Apr;74(4):775-782
pubmed: 33248170
Int J Epidemiol. 1984 Mar;13(1):53-7
pubmed: 6698704
Alcohol Clin Exp Res. 2015 May;39(5):836-42
pubmed: 25872595
Drug Alcohol Rev. 2010 Jul;29(4):437-45
pubmed: 20636661
Alcohol Alcohol. 2021 Feb 24;56(2):185-200
pubmed: 33479737
Am J Gastroenterol. 2021 Jan 1;116(1):106-115
pubmed: 32868629
Gastroenterology. 2020 Oct;159(4):1276-1289.e7
pubmed: 32561361
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Arch Gen Psychiatry. 2007 Jul;64(7):830-42
pubmed: 17606817
BMC Cancer. 2019 Nov 21;19(1):1128
pubmed: 31752753